480 related articles for article (PubMed ID: 30289627)
1. Rapid therapeutic advances in CFTR modulator science.
Clancy JP
Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
Perrem L; Ratjen F
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
[TBL] [Abstract][Full Text] [Related]
3. Functional Consequences of CFTR Interactions in Cystic Fibrosis.
Ramananda Y; Naren AP; Arora K
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542363
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
Wang S; Niroula S; Hoffman A; Khorrami M; Khorrami M; Yuan F; Gasser GN; Choi S; Liu B; Li J; Metersky ML; Vincent M; Crum CP; Boucher RC; Karmouty-Quintana H; Huang HJ; Sheshadri A; Dickey BF; Parekh KR; Engelhardt JF; McKeon FD; Xian W
Am J Respir Crit Care Med; 2023 Nov; 208(9):930-943. PubMed ID: 37695863
[No Abstract] [Full Text] [Related]
5. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
6. Toward inclusive therapy with CFTR modulators: Progress and challenges.
Guimbellot J; Sharma J; Rowe SM
Pediatr Pulmonol; 2017 Nov; 52(S48):S4-S14. PubMed ID: 28881097
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
9. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
10. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
12. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.
Saluzzo F; Riberi L; Messore B; Loré NI; Esposito I; Bignamini E; De Rose V
Cells; 2022 Apr; 11(7):. PubMed ID: 35406809
[TBL] [Abstract][Full Text] [Related]
13. A foetus with cystic fibrosis - To treat or not to treat?
Padmakumar N; Khan HS
Respir Med Res; 2023 Jun; 83():101006. PubMed ID: 37037055
[TBL] [Abstract][Full Text] [Related]
14. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
16. Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis.
Thakur S; Ankita ; Dash S; Verma R; Kaur C; Kumar R; Mazumder A; Singh G
Cell Biochem Biophys; 2024 Mar; 82(1):15-34. PubMed ID: 38048024
[TBL] [Abstract][Full Text] [Related]
17. Airway Inflammation and Host Responses in the Era of CFTR Modulators.
Keown K; Brown R; Doherty DF; Houston C; McKelvey MC; Creane S; Linden D; McAuley DF; Kidney JC; Weldon S; Downey DG; Taggart CC
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887484
[TBL] [Abstract][Full Text] [Related]
18. The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
Oliver KE; Carlon MS; Pedemonte N; Lopes-Pacheco M
Expert Opin Pharmacother; 2023; 24(14):1545-1565. PubMed ID: 37379072
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
20. Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches.
Ghigo A; Prono G; Riccardi E; De Rose V
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
